Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002
FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011
A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP) Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010
Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC) Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S) Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002
Analysis of prognostic factors in patients with stage IIIB, IV non-small cell lung cancer Source: Annual Congress 2010 - Staging of lung cancer Year: 2010
Prognostic factors in resected pathological N1-stage II nonsmall cell lung cancer Source: Eur Respir J 2013; 41: 649-655 Year: 2013
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
Prognostic value of Her2/neu in stage IIIA non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006
Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm Source: Eur Respir J 2010; 36: 1355-1361 Year: 2010
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
Radiotherapy for stage III non-small cell lung cancer (NSCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
The prognostic impact of stage and performance status on surgically resected non-small cell lung cancer Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018
Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
Evaluation of the role of EGFR as prognostic factor in stage III non-small cell lung cancer (NSCLC): a retrospective analysis Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019
Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010